La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Vericel a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Vericel..

Vericel (NASDAQ:VCEL) Azioni, Catena delle Opzioni

VERICEL CORP

Vericel

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Vericel Corp

Canaccord Genuity analyst Austin Moeller maintains Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) with a Buy and lowers the price target from $18 to $17.5.

News

Price Target

Analyst Ratings

CBUS

Canaccord Genuity Maintains Buy on Cibus, Lowers Price Target to $17.5

UroShield Demonstrates Significant Reductions in CAUTIs, Catheter Blockages and Hospital Visits
NanoVibronix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) (the "Company"), a medical technology company specializing in therapeutic devices, today announced findings from a recent retrospective case series evaluating the clinical impact and patient experience of the UroShield&#x2122; system.
The case series, conducted between September 2023 and January 2025 by researchers at University Hospitals Coventry and Warwickshire Partnership NHS, assessed a small group of patients who used the UroShield device for durations ranging from 12 weeks to 17 months. The series reviewed pre- and post-treatment data on catheter-associated urinary tract infections (CAUTIs), catheter blockages, unplanned hospital visits and patient satisfaction.

NAOV

NanoVibronix: UroShield Shows Reductions In CAUTIs, Catheter Blockages And Hospital Visits

Shiseido Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSDOY#OTC">SSDOY</a>) reported quarterly earnings of $0.06 per share. This is a 200 percent increase over losses of $(0.06) per share from the same period last year. The company reported $1.50 billion in sales this quarter. This is a 10.95 percent decrease over sales of $1.68 billion the same period last year.

Earnings

SSDOY

Shiseido Co Q1 EPS $0.06 Up From $(0.06) YoY, Sales $1.50B Down From $1.68B YoY

WIIM

Wayfair shares are trading higher after Argus Research upgraded the stock from Hold to Buy and announced a $40 price target.

BHP Group shares are trading higher after a judge blocked an Arizona land transfer to Rio Tinto.

CSX shares are trading higher after the company announced it reached a labor agreement with the Brotherhood of Locomotive Engineers and Trainmen on a new 5-year single-system covering approximately 3,400 engineers.

Movers

Trading Ideas

ALCY

Alchemy Investments Acquisition Corp 1 Shares Halted, News Pending

Suzuki Motor (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SZKMY#OTC">SZKMY</a>) reported quarterly earnings of $1.42 per share. This is a 408.7 percent increase over losses of $(0.46) per share from the same period last year. The company reported $10.11 billion in sales this quarter. This is a 1.77 percent decrease over sales of $10.29 billion the same period last year.

SZKMY

Suzuki Motor Q4 EPS $1.42 Up From $(0.46) YoY, Sales $10.11B Down From $10.29B YoY

Somnigroup shares are trading higher amid overall market strength after the US and China agreed to temporarily suspend most tariffs. The company initially dipped after it announced a secondary offering.

ALCYU

Trading Halt: Halted at 8:46:30 a.m. ET - Trading Halt: Halt News Pending

ALCYW

Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) ("Omeros" or the "Company") today announced that it has entered into exchange agreements (the "Exchange Agreements") with a limited number of investors who are holders of the Company's 5.25% Convertible Senior Notes due 2026 (the "2026 Convertible Notes") to exchange, on a one-for-one basis, $70.5 million aggregate principal amount of the 2026 Convertible Notes for newly issued 9.50% Convertible Senior Notes due 2029, with a conversion rate set at a 35% premium as described below (the "New Convertible Notes"). The exchange, which extends the maturity of a significant portion of the Company's outstanding indebtedness, is expected to close on or about May 14, 2025.
In addition, Omeros today announced that it has entered into an agreement (the "Note Conversion Agreement") with an investor to convert $10 million aggregate principal amount of 2026 Convertible Notes into shares of the Company's common stock, par value $0.01 per share (the "Equitization Transaction").
Following the completion of these transactions, approximately $17.4 million aggregate principal amount of the 2026 Convertible Notes will remain outstanding. This reduction in principal balance of the 2026 Convertible Notes outstanding will prevent the Company from being required to make a $20.0 million prepayment of the term loan outstanding under its 2024 Credit and Guaranty Agreement. This prepayment otherwise would have become due in November 2025. As a result of these transactions, the Company expects that its outstanding debt will be reduced by $10.0 million and its potential debt repayment obligations over the next 12 months will be reduced from $117.9 million to approximately $17.4 million.

OMER

Omeros Agrees To Acquire $80.5M Of Its Convertible Senior Notes Due 2026

NRXS

CORRECTION: Neuraxis Q1 EPS $(0.33) Down From $(0.32) YoY, Sales $895.65K Up From $646.63K YoY

Major cryptocurrencies are holding firm on Monday morning as investor sentiment improves on news of a <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45344686/can-the-us-china-tariff-de-escalation-send-bitcoin-ethereum-to-new-highs">U.S.-China tariff pause. </a>
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$103,945.97</td>
<td>-0.7%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,550.52</td>
<td>+1.2%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$175.02</td>
<td>+0.5%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.53</td>
<td>+6.7%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.2437</td>
<td>+4.4%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001679</td>
<td>+4.4%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows Bitcoin large transaction volume grew 3%, while daily active addresses dropped 7.4% in a single day.</li>
<li>Coinglass data shows 147,351 traders were liquidated in the past 24 hours for $392.16 million.</li>
<li>Discord groups flagged a sharp rise in Bitcoin open interest, with $1.7 billion added in a day, noting that longs are pushing the price action upward despite rising funding rates.</li>
</ul>
Trader Notes: Nic Puckrin, founder and investor of Coin Bureau, says Bitcoin's rally reflects improving risk appetite as tariff reduction talks between the U.S. and China lower geopolitical friction. 
Gold has dropped over 3%, reinforcing a rotation away from safe-haven assets.
"Bitcoin has shifted back to a risk-on asset," Puckrin noted. "It's once again trading in step with equities and could soon break its all-time high."
However, he cautioned that the altcoin rally lacks staying power without significant retail engagement. 
Despite ETF-driven hype, the absence of mainstream inflows could limit upside for most non-BTC assets.
McKenna <a href="https://x.com/Crypto_McKenna/status/1921830409601794289">says</a> Bitcoin's one-day mean reversion signals will activate above $110,000, suggesting consolidation may follow. Still, he's confident that with liquidity tailwinds, new all-time highs are a matter of "when," not "if."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Bitcoin continues its march to the upper range of the linear reg channel. 1D mean reversions to the upside begin to flash when BTC is above $110k so getting close. Think Bitcoin will enter a period of consolidation here. But I am in the view new all time highs in 2025 are… <a href="https://t.co/E1Dc5id4z2">pic.twitter.com/E1Dc5id4z2</a>
&mdash; McKenna (@Crypto_McKenna) <a href="https://twitter.com/Crypto_McKenna/status/1921830409601794289?ref_src=twsrc%5Etfw">May 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Meanwhile, CW <a href="https://x.com/CW8900/status/1921801797938630687">reports</a> that Solana has cleared its sell wall, with no resistance until $270. Trader Tardigrade is <a href="https://x.com/TATrader_Alan/status/1921870983121818012">calling</a> for a parabolic Dogecoin surge, pointing to signs of accelerated accumulation.
Chris Burniske, former ARK Invest executive, <a href="https://x.com/cburniske/status/1921858460003467451">says</a> he's long Ethereum, expecting both ETH and BTC to outperform this cycle. Ted Pillows <a href="https://x.com/TedPillows/status/1921893104493166859">adds</a> that Ethereum is holding its breakout and could rally soon if momentum continues.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45344022/bitcoin-taps-105000-heres-when-it-could-hit-122000">Bitcoin Taps $105,000: Here&#8217;s When It Could Hit $122,000</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Hold Gains As US, China Agree To Lower Tariffs

Adds nine additional countries to the Company's ongoing pivotal Phase 3 trial; Authorization granted in all EU countries requested
Enrollment and dosing underway in Phase 3 clinical trial (the "MIRACLE" trial) evaluating Annamycin for the treatment of R/R AML; Interim data readout expected in the second half of 2025
Subjects targeted for the "MIRACLE" trial include venetoclax regimen failures where outcomes with currently available therapies are considered dismal
HOUSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced that the European Medicines Agency (EMA) has approved its Clinical Trial Application (CTA) to conduct its pivotal Phase 2B/3, multi-center, randomized, double-blind, placebo-controlled, adaptive design study of Annamycin in combination with cytarabine (also known as "Ara-C" and for which the combination of Annamycin and Ara-C is referred to as "AnnAraC"). The study is for the treatment of adult patients with acute myeloid leukemia (AML) who are refractory to or relapsed (R/R) after induction therapy (R/R AML) and is approved in all nine countries submitted in the European Union (EU). This Phase 3 "MIRACLE" trial (derived from Moleculin R/R AML AnnAraC Clinical Evaluation) is a global approval trial, including sites in the US, Europe and the Middle East.

MBRX

Moleculin Biotech Receives EMA Approval For Clinical Trial Application To Conduct Pivotal Phase 2B/3 AnnAraC Clinical Trial

Economist Craig Shapiro shared his insights on the unfolding U.S.-China trade dynamics, warning that while a tariff truce may calm immediate market fears, it could have unintended consequences for the broader economy.
What Happened: Shapiro, a macro strategist at Bear Traps Report, suggested that the so-called &#8220;tariff climb down&#8221; might prevent bond yields from falling, thereby maintaining pressure on an already strained economy as the Federal Reserve remains on the sidelines.
Shapiro's analysis, posted on X, builds on his earlier reflections from May 9, where he drew parallels to the 2018 Donald Trump, Xi Jinping G20 summit in Argentina. Back then, a temporary trade truce sparked market euphoria, driving a brief rally as volatility subsided.
However, the optimism was short-lived. Markets tanked in the following weeks as the reality of implementing a deal set in, compounded by a slowing economy and a Federal Reserve that was tightening policy through quantitative tightening.
The situation only stabilized after the former Treasury Secretary Steven Mnuchin's emergency Christmas Eve call to major banks and Fed Chair Jerome Powell's subsequent policy pivot in early 2019.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Sticking with this call Tariff Climb down will alleviate the worst fears but the reality is that the cave will make it hard for yields to fall which keeps the economy under pressure as the Fed sits on its hands. <a href="https://t.co/BdWKBOUf8o">https://t.co/BdWKBOUf8o</a>
&mdash; Craig Shapiro (@ces921) <a href="https://twitter.com/ces921/status/1921845051589640249?ref_src=twsrc%5Etfw">May 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
His comments come amid a backdrop of heightened trade tensions, with recent reports indicating that President Trump paused reciprocal tariffs for 90 days, leaving a baseline 10% rate in place. Despite this reprieve, bond yields have remained stubbornly high.
The 10-year Treasury yields jumped to 4.45% as of the publication of this article.
Thus, according to Shapiro, inflationary effects could continue to push up prices and inflation expectations, and this will prevent bond yields from falling, as investors demand higher yields to offset inflation risk and perceived economic uncertainty.
See Also: <a href="https://www.benzinga.com/government/regulations/25/05/45341850/economists-warn-of-empty-shelves-if-goods-stop-coming-from-china-amid-falling-inventory-to-sales-ratio-and-potential-tariffs">Economists Warn Of &#8216;Empty Shelves&#8217; If Goods Stop Coming From China Amid Falling Inventory-To-Sales Ratio And Potential Tariffs</a>
Why It Matters: On Monday, the U.S. and China declared a <a href="https://www.benzinga.com/markets/equities/25/05/45341884/apple-amazon-nvidia-rise-in-monday-premarket-as-us-china-agree-to-90-day-tariff-truce-neither-side-wants-a-decoupling">90-day suspension</a> of reciprocal tariffs, reducing them from 125% to 10%, following notable progress in<a href="https://www.benzinga.com/news/global/25/05/45337811/trump-announces-total-reset-as-us-china-trade-talks-aim-to-end-tariff-war"> trade discussions</a> held in Geneva over the weekend, as indicated by both the White House and Chinese officials. 
The U.S. will keep its 20% tariffs on Chinese imports related to fentanyl, resulting in a total tariff rate on China of 30%. Treasury Secretary Scott Bessent commented, &#8220;We had very productive talks and I believe that the venue, here in Lake Geneva, added great equanimity to what was a very positive process."
According <a href="https://www.scmp.com/economy/global-economy/article/3309975/china-us-reduce-majority-tariffs-after-first-round-trade-talks?module=top_story&amp;pgtype=homepage">to</a> the South China Morning Post, the joint U.S.-China statement also revealed that Beijing has agreed to lift or suspend all non-tariff countermeasures in place since April 2, which include export restrictions on critical minerals and sanctions on certain U.S. companies. 
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Monday. The SPY was up 3.04% to $581.50, while the QQQ advanced 3.90% to $507.02, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
On Friday, the SPY was down 0.13% to $564.34, while the QQQ declined 0.066% to $487.97
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45344120/cathie-wood-says-ai-innovation-in-healthcare-will-be-more-profound-than-autonomous-taxi-ne">Cathie Wood Says AI Innovation In Healthcare Will Be More &#8216;Profound&#8217; Than Autonomous Taxi Networks, Humanoid Robots</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Analyst Color

Equities

Government

Macro Economic Events

Macro Notification

Market Summary

Regulations

Broad U.S. Equity ETFs

Futures

Economics

Markets

ETFs

General

US-China Tariff Truce Will Alleviate 'Worst Fears,' But Prevent Falling Yields, Keeping 'Economy Under Pressure,' Says Craig Shapiro

Bill Gates, co-founder of Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), has criticized Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk's recent push for $2 trillion in U.S. government budget cuts, focusing on the dismantling of the U.S. Agency for International Development. 
What Happened: Gates said, in an interview <a href="https://edition.cnn.com/2025/05/09/tech/bill-gates-elon-musk-usaid-cuts-criticism">with</a> CNN, that Musk's aggressive reductions, executed through the Department of Government Efficiency (DOGE) under President Donald Trump&#8216;s administration, could result in millions of deaths worldwide due to the abrupt halt of foreign assistance and health programs.
Gates argued that while efficiency and the use of artificial intelligence in government are laudable goals, Musk's approach has led to slashing critical aid to vulnerable populations. 
"If you show up and say, in two months, you can cut $2 trillion out of a $7 trillion budget, you're not going to succeed," Gates said. "So you go for the softest things and things that are overseas, that you can mischaracterize… people that he hasn't spent any time with." 
See Also: <a href="https://www.benzinga.com/government/regulations/25/05/45342343/us-stock-futures-rise-as-us-china-agree-to-90-day-tariff-pause-wider-earnings-growth-should-drive-more-balanced-market-performance-says-expert">US Stock Futures Rise As US, China Agree To 90-Day Tariff Pause: &#8216;Wider Earnings Growth Should Drive More Balanced Market Performance,&#8217; Says Expert</a>
Why It Matters: Gates specifically criticized Musk's false claim that the <a href="https://www.benzinga.com/25/05/45311187/the-picture-of-the-worlds-richest-man-killing-the-worlds-poorest-children-is-not-a-pretty-one-says-bill-gates-slamming-elon-musk-over-abrupt-usaid-cuts">U.S. spent $50 billion on condoms for Gaza</a>, which Musk later retracted, and condemned Musk's negative portrayal of USAID workers, calling them "heroes" and vital to America's global reputation.
The cuts have already disrupted contracts and payments to nonprofits, with aid organizations warning of deadly consequences. U.S. District Judge Theodore Chuang recently blocked further cuts and ordered DOGE to restore some USAID systems, though most contracts remain terminated.
Gates, who recently pledged to give away nearly all his wealth through the Gates Foundation, emphasized that private philanthropy cannot replace the <a href="https://www.benzinga.com/25/05/45311187/the-picture-of-the-worlds-richest-man-killing-the-worlds-poorest-children-is-not-a-pretty-one-says-bill-gates-slamming-elon-musk-over-abrupt-usaid-cuts">scale of government funding for global health</a>. 
"If it was a modest cut and a challenge to be more efficient… I'm fine with that. But 80%, that's going to be millions of deaths and it's a mistake," Gates said.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/health-care/25/05/45345409/trumps-big-beautiful-bill-banks-on-huge-medicaid-cuts-as-its-cost-saving-centerpiece-see-who-risks-losing-coverage-under-the-gop-proposal">Trump&#8217;s &#8216;Big, Beautiful Bill&#8217; Banks On Huge Medicaid Cuts As Its &#8216;Cost-Saving Centerpiece&#8217; — See Who Risks Losing Coverage Under The GOP Proposal</a></li>
</ul>
Image Via Shutterstock

MSFT

TSLA

Bill Gates Says Elon Musk's DOGE 'Not Going To Succeed' With $2 Trillion Budget Cut Ambition: 'If You Show Up And Say…'

<a href="https://pr.report/aa4s">Gladstone Commercial Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOD#NASDAQ">GOOD</a>) ("Gladstone Commercial") is pleased to announce the acquisition of a newly constructed 303,991 square-foot, Class A, fully temperature controlled facility located in Germantown, Wisconsin. This state-of-the-art property was purchased for $62,700,000, providing a weighted average GAAP capitalization rate of 8.74%. The facility includes specialized freezer and cooler storage and was built to support high-capacity pet food production and distribution.
The facility is 100% leased to G&amp;H Pets, LLC through September 2044. The tenant is the in-house manufacturing platform for California Pet Partners, producing premium freeze-dried raw pet food for dogs and cats currently sold under several brands.

GOOD

Gladstone Commercial Acquires $62.7M Class A Temperature-Controlled Facility In Germantown, WI, Fully Leased Through September 2044

WVV Founder Jim Bernau Continues as Chairman and President, Marking Strategic Leadership Succession
SALEM HILLS, Ore., May 12, 2025 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4424376-1&amp;h=3969711784&amp;u=https%3A%2F%2Fwww.wvv.com%2F&amp;a=Willamette+Valley+Vineyards">Willamette Valley Vineyards</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVVI#NASDAQ">WVVI</a>, WVVIP))), one of Oregon's most respected estate wineries, announced today that Mike Osborn, founder of Wine.com, has been named Chief Executive Officer, effective immediately. The appointment follows founder Jim Bernau's January 2025 announcement that he would be stepping back from the CEO role while continuing to serve as President and Chairperson as part of a long-term succession plan.

Management

WVVI

Willamette Valley Vineyards Appoints Mike Osborn As CEO, Effective Immediately

Press Releases

Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024

Vericel Reports Third Quarter 2024 Financial Results

Health Care

Vericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025

Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets

Vericel to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 27, 2025

Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results

Vericel to Present at Multiple Upcoming Investor Conferences

Vericel to Report First-Quarter 2025 Financial Results on May 8, 2025

Vericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025

Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance

Comments

Vericel

Vericel (VCEL) Opzioni

Vericel (NASDAQ:VCEL) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO